
CLAIMS

1. Use of a compound of formula (I) for the manufacture of a medicament for treating a chronic obstructive pulmonary disease, sepsis, coronary atherosclerosis, bronchoconstriction, pulmonary fibrosis, coronary artery constriction, cytokine amplification by dendritic cells, or the generation of disseminated intravascular coagulopathy, inflammation by influenza infection, cardiovascular disease, hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, or systemic sclerosis in a patient, wherein the compound of formula (I) is



(I)

wherein

Ar^1 is a phenyl optionally substituted with up to three substituents selected from the group consisting of $(C_1\text{-}C_4)$alkyl, halo, halo$(C_1\text{-}C_4)$alkyl, OH, and $(C_1\text{-}C_4)$alkoxy;

Ar^2 is phenyl or pyridyl, wherein Ar^2 is optionally substituted with up to three substituents selected from the group consisting of halo, cyano, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_6)$alkoxycarbonyl$(CH_2)_{0\text{-}2}$, halo$(C_1\text{-}C_4)$alkyl, OH, monohydroxy$(C_1\text{-}C_4)$alkyl, $NR_2C(=O)(CH_2)_{0\text{-}2}O(CH_2)_{0\text{-}2}$, $NR_2C(=O)(CH_2)_{0\text{-}2}$, $(C_1\text{-}C_4)C(=O)N(R)$, (5- to 10-membered)heterocyclyl, (5- to 10-membered) heteroaryl; and

Ar^3 is pyridyl optionally substituted with up to three substituents selected from the group consisting of $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl, halo, halo$(C_1\text{-}C_4)$alkyl, OH, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_6)$alkoxycarbonyl$(CH_2)_{0\text{-}2}$, carboxy$(CH_2)_{0\text{-}2}$, monohydroxy$(C_1\text{-}C_4)$alkyl, $NR_2(CH_2)_{0\text{-}2}$, and $(C_3\text{-}C_{10})$cycloalkyl;


each R is independently H or (C1-C4)alkyl;

R' is H;

X is N(R); and

L is C(=O).







2. The use of claim 1, wherein the compound of formula (I) is a compound of formula (IB)















(IB)







wherein Ar^1 and Ar^2 are phenyl.






3. The use of claim 1, wherein the compound is selected from the following table:






52595	
52331	
52332	
52394 IB	
52396 IB	
52397 IB	







52398 IB	
52399 IB	
52433 IB	
52434 IB	
52435 IB	
52442 IB	








52458 IB	
52459 IB	
52460 IB	
52464 IB	
52474 IB	
52475 IB	






52483 IB	
52484 IB	
52486 IB	
52487 IB	
52488 IB	
52491 IB	







52504 IB	
52505 IB	
52506 IB	
52507 IB	
52508 IB	







52509 IB	
52511 IC	
52512 IB	
52514 IB	
52520 IB	







52522 IB	
52523 IB	
52524 IB	
52525 IB	
52526 IB	
52527 IB	







52528 IB	
52529 IB	
52530 IB	
52531 IC	
52543 IB	
52544 IB	
52545 IB	






52547 IB	
52548 IB	
52551 IB	
52552 IB	
52555 IB	







52556 IB	
52558 IB	
52559 IB	
52560 IB	
52562 IB	
52563 IB	







52564 IB	
52571 IB	
52572 IB	
52573 IB	
52574 IB	
52575 IB	







52576 IB	
52577 IB	
52578 IB	
52579 IB	
52580 IB	
52581 IB	







52582 IB	
52583 IB	
52584 IB	
52585 IB	
52586 IB	
52587 IB	







52589 IB	
52590 IB	
52591 IB	
52592 IB	
52593 IB	







52594 IB	
52595 IB	
52596 IB	
52597 IB	
52598 IB	
52599 IB	







52600 IB	
52601 IB	
52602 IB	
52603 IB	
52604 IB	
52605 IB	







52606 IB	
52607 IB	
52608 IB	
52609 IB	
52614 IB	
52616 IB	







52617 IB	
52618 IB	
52619 IB	
52620 IB	
52621 IB	
52627 IB	







52628 IB	
52629 IB	
52630 IB	
52631 IB	
52632 IB	
52633 IB	







52634 IB	
52637 IB	
52649 IB	
52650 IB	
52651 IB	
52652 IB	







52653 IB	
52664 IB	
52665 IB	
52666 IB	
52670 IB	
52671 IB	



52672 IB	
52673 IB	
52674 IB	
52677 IB	
52678 IB	
52683 IB	

52684 IB	
52685 IB	
52686 IB	
52705 IB	
52706 IB	
52707 IB	

52708 IB	
52709 IB	
52710 IB	
52711 IB	
52715 IB	
52716 IB	

52717 IB	
52718 IB	
52721 IB	
52722 IB	
52723 IB	
52724 IB	

52725 IB	
52726 IA	
52727 IB	
52729 IB	
52731 IB	
52735 IB	

52740 IB	
52744 IB	

4. The use of claim 1, wherein the disease is a chronic obstructive pulmonary disease.

5. The use of claim 1, wherein the disease comprises sepsis.

6. The use of claim 1, wherein the disease is coronary atherosclerosis.

7. The use of claim 1, wherein the disease comprises a clinical syndrome characterized by bronchoconstriction, pulmonary fibrosis, coronary artery constriction, cytokine amplification by dendritic cells, or the generation of disseminated intravascular coagulopathy.

8. The use of claim 1, wherein the disease comprises inflammation by influenza infection.

9. The use of claim 1, wherein the disease is cardiovascular disease, hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, or systemic sclerosis.